ArticleEye (London, England)2018

Comment on: 'One-year real-world outcomes in patients receiving fixed-dosing aflibercept for neovascular age-related macular degeneration'.

A R NestelPubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.